Has Ayman Elkadry, MD received payments from drug or device companies?

Yes. Drug and device makers reported $767,251 in general payments to Ayman Elkadry, MD across 604 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ayman Elkadry, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ayman Elkadry, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ayman Elkadry, MD

Endocrinology, Diabetes & Metabolism · Huntington, WVNPI 1861606808

Payments from drug & device makers

$767,251in general payments, 2019–2025

Across 604 payments — averaging $1270.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Roche Diagnostics Operations, Inc.$485K
AbbVie$269K
Novo Nordisk$2K
Abbott$2K
Lilly USA, LLC$1K
Amgen$1K
plus $7K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Roche Diagnostics Operations, Inc.	41	$484,733
AbbVie	23	$269,188
Novo Nordisk	115	$2,154
Abbott	7	$1,741
Lilly USA, LLC	68	$1,244
Amgen(2 entities)	60	$1,145
Senseonics, Incorporated	21	$792
Medtronic(2 entities)	15	$625
Corcept Therapeutics	15	$462
Xeris Pharmaceuticals, Inc.	26	$394
Bayer	8	$342
Amarin Pharma, Inc.	18	$332
Ascendis Pharma Endocrinology Inc	11	$283
Antares Pharma, Inc.	10	$266
Radius Health, Inc.	5	$264
AstraZeneca(2 entities)	16	$256
Neurocrine Biosciences, Inc.	9	$225
Sanofi-aventis U.S. LLC	15	$178
Recordati_rare_diseases_inc.	8	$175
Ascensia Diabetes Care US Inc.	5	$168
Amneal Pharmaceuticals LLC	9	$133
Boehringer Ingelheim	7	$126
Sequel Med Tech, LLC	1	$124
Pfizer	7	$118
BD	3	$112
Cequr Corporation	6	$108
Mannkind Corporation	2	$106
Rhythm Pharmaceuticals, Inc.	6	$99
Ultragenyx Pharmaceutical Inc.	5	$98
Madrigal Pharmaceuticals	3	$94
IBSA Pharma Inc.	6	$85
Valeritas, Inc.	1	$85
Merck	2	$75
Nevro Corp.	2	$74
Verity Pharmaceuticals Inc.	3	$59
Tandem Diabetes Care, Inc.	1	$58
Shire North American Group Inc	4	$57
Averitas Pharma Inc.	3	$51
Amphastar Pharmaceuticals, Inc.	2	$50
Insulet Corporation	2	$40
Tolmar, Inc.	2	$39
Currax Pharmaceuticals LLC	3	$38
Ipsen Biopharmaceuticals, Inc	2	$36
Endo Pharmaceuticals Inc.	2	$36
Takeda Pharmaceuticals U.S.A., Inc.	2	$31
Chiesi USA, Inc.	2	$30
Amryt Pharma Holdings Ltd	2	$29
Nalpropion Pharmaceuticals LLC	2	$26
Azurity Pharmaceuticals, Inc.	1	$25
Ferring Pharmaceuticals Inc.	2	$23
Regeneron Healthcare Solutions, Inc.	1	$22
Halozyme Inc	1	$21
Dexcom, Inc.	1	$21
Embecta Corp.	1	$20
Astellas Pharma US Inc	1	$20
Gilead	1	$18
Boston Scientific	1	$17
Johnson & Johnson	1	$14
Esperion Therapeutics, Inc.	1	$14
Eisai Inc.	1	$14

How this compares

$767,251 in reported general payments places this provider in the 95th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.

See all endocrinology, diabetes & metabolism providers in West Virginia →

Medicare billing

Part B allowed, 2024

$305,355

Medicare patients

554

Services billed

7,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Huntington

Daniel MaciasHuntington$686K
Henry DriscollHuntington$1K
Mateen HotianaHuntington$1K
John LeidyHuntington$864
Ronald InnerfieldHuntington$833
Sobia FaisalHuntington$705
Henin AlsamarraieHuntington$695
Nesreen BenhamedHuntington$526
Maria Luzuriaga BassanteHuntington$421
Muhammad HaqHuntington$280

See the full list for West Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →